ScreenerHero
NANEXANanexa AB (publ)
STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · nanexa.com
4.695SEK+0.97%Mkt Cap: 82.19M $P/E: —

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposit…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap82.19M $
Enterprise Value75.30M $
Revenue (TTM)5.20M $
Gross Profit5.35M $
Net Income (TTM)-1.09M $
Revenue/Share0.0321 USD
Last Price4.695 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)21.80
PEG—
EV/EBITDA-107.53
EV/Revenue14.47
P/S16.29
P/B6.97
EPS (TTM)-0.09
EPS (Forward)0.22
52W Range
1.40092% of range5.000
52W High5.000 SEK
52W Low1.400 SEK
Profitability
Gross Margin154.74%
Oper. Margin-222.20%
EBITDA Margin-13.46%
Profit Margin-31.50%
ROE-11.22%
ROA-8.24%
Growth
Revenue Growth-20.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-139.84K $
CapEx (TTM)2.37M $
FCF Margin2.87%
FCF Yield0.18%
Net Debt-6.89M $
Net Debt/EBITDA9.84
Balance Sheet
Debt/Equity0.02
Current Ratio2.06
Quick Ratio2.06
Book Value/Sh0.6880 SEK
Cash/Share0.3950 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.184.79M
Float140.01M
Insiders32.72%
Institutions7.27%
Technical
SMA 503.984 (+17.8%)
SMA 2003.609 (+30.1%)
Beta1.75
S&P 52W Chg18.16%
Avg Vol (30d)288.93K
Avg Vol (10d)347.10K
Technical Indicators
RSI (14)66.0
MACD0.1956
MACD Signal0.1574
MACD Hist.+0.0382
BB Upper4.871 SEK
BB Middle4.194 SEK
BB Lower3.517 SEK
BB Width32.29%
ATR (14)0.2483 SEK
Vol Ratio (20d)1.80x